Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing. Achar, J., Seddon, J. A, Knight, G. M, Dodd, P. J, Esmail, H., Hughes, J., & McQuaid, C F. European Respiratory Journal, 62(5):2300969, European Respiratory Society, nov, 2023. ![Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex With recent expansion in the use of bedaquiline and limited access to accurate drug susceptibility testing (DST), we read with concern of examples of the high prevalence of bedaquiline resistance detected in Mycobacterium tuberculosis isolates [1]. Choosing the most effective regimen for treatment of drug-resistant tuberculosis (TB) is crucially important [2] and requires accurate and timely DST. In the past decade, there has been wide roll-out of rapid molecular tests that can identify M. tuberculosis and mutations conferring rifampicin resistance (RR). However, for potent second-line drugs, such as fluoroquinolones [3], bedaquiline, pretomanid and linezolid, DST is either unavailable, has poor coverage or generates delayed results. To support clinicians, policymakers must provide pragmatic treatment recommendations for situations where a patient is diagnosed with RR-TB, but where additional DST results for second-line drugs are delayed or unavailable. Second-line drug susceptibility test results are frequently unavailable for people with TB. A method is proposed for comparing risks and benefits of different treatment regimens for rifampicin-resistant TB when accurate results are unavailable. https://bit.ly/46KHyl0
@article{Achar2023,
abstract = {With recent expansion in the use of bedaquiline and limited access to accurate drug susceptibility testing (DST), we read with concern of examples of the high prevalence of bedaquiline resistance detected in Mycobacterium tuberculosis isolates [1]. Choosing the most effective regimen for treatment of drug-resistant tuberculosis (TB) is crucially important [2] and requires accurate and timely DST. In the past decade, there has been wide roll-out of rapid molecular tests that can identify M. tuberculosis and mutations conferring rifampicin resistance (RR). However, for potent second-line drugs, such as fluoroquinolones [3], bedaquiline, pretomanid and linezolid, DST is either unavailable, has poor coverage or generates delayed results. To support clinicians, policymakers must provide pragmatic treatment recommendations for situations where a patient is diagnosed with RR-TB, but where additional DST results for second-line drugs are delayed or unavailable. Second-line drug susceptibility test results are frequently unavailable for people with TB. A method is proposed for comparing risks and benefits of different treatment regimens for rifampicin-resistant TB when accurate results are unavailable. https://bit.ly/46KHyl0},
author = {Achar, Jay and Seddon, James A and Knight, Gwenan M and Dodd, Peter J and Esmail, Hanif and Hughes, Jennifer and McQuaid, C Finn},
doi = {10.1183/13993003.00969-2023},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Achar et al. - 2023 - Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susce.pdf:pdf},
issn = {0903-1936},
journal = {European Respiratory Journal},
keywords = {OA,fund{\_}not{\_}ack,letter},
mendeley-tags = {OA,fund{\_}not{\_}ack,letter},
month = {nov},
number = {5},
pages = {2300969},
pmid = {37945035},
publisher = {European Respiratory Society},
title = {{Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing}},
url = {https://erj.ersjournals.com/content/62/5/2300969 https://erj.ersjournals.com/content/62/5/2300969.abstract},
volume = {62},
year = {2023}
}
Downloads: 0
{"_id":"7ndQRRLkgwHHGpjsv","bibbaseid":"achar-seddon-knight-dodd-esmail-hughes-mcquaid-guidingpragmatictreatmentchoicesforrifampicinresistanttuberculosisintheabsenceofsecondlinedrugsusceptibilitytesting-2023","author_short":["Achar, J.","Seddon, J. A","Knight, G. M","Dodd, P. J","Esmail, H.","Hughes, J.","McQuaid, C F."],"bibdata":{"bibtype":"article","type":"article","abstract":"With recent expansion in the use of bedaquiline and limited access to accurate drug susceptibility testing (DST), we read with concern of examples of the high prevalence of bedaquiline resistance detected in Mycobacterium tuberculosis isolates [1]. Choosing the most effective regimen for treatment of drug-resistant tuberculosis (TB) is crucially important [2] and requires accurate and timely DST. In the past decade, there has been wide roll-out of rapid molecular tests that can identify M. tuberculosis and mutations conferring rifampicin resistance (RR). However, for potent second-line drugs, such as fluoroquinolones [3], bedaquiline, pretomanid and linezolid, DST is either unavailable, has poor coverage or generates delayed results. To support clinicians, policymakers must provide pragmatic treatment recommendations for situations where a patient is diagnosed with RR-TB, but where additional DST results for second-line drugs are delayed or unavailable. Second-line drug susceptibility test results are frequently unavailable for people with TB. A method is proposed for comparing risks and benefits of different treatment regimens for rifampicin-resistant TB when accurate results are unavailable. https://bit.ly/46KHyl0","author":[{"propositions":[],"lastnames":["Achar"],"firstnames":["Jay"],"suffixes":[]},{"propositions":[],"lastnames":["Seddon"],"firstnames":["James","A"],"suffixes":[]},{"propositions":[],"lastnames":["Knight"],"firstnames":["Gwenan","M"],"suffixes":[]},{"propositions":[],"lastnames":["Dodd"],"firstnames":["Peter","J"],"suffixes":[]},{"propositions":[],"lastnames":["Esmail"],"firstnames":["Hanif"],"suffixes":[]},{"propositions":[],"lastnames":["Hughes"],"firstnames":["Jennifer"],"suffixes":[]},{"propositions":[],"lastnames":["McQuaid"],"firstnames":["C","Finn"],"suffixes":[]}],"doi":"10.1183/13993003.00969-2023","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Achar et al. - 2023 - Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susce.pdf:pdf","issn":"0903-1936","journal":"European Respiratory Journal","keywords":"OA,fund_not_ack,letter","mendeley-tags":"OA,fund_not_ack,letter","month":"nov","number":"5","pages":"2300969","pmid":"37945035","publisher":"European Respiratory Society","title":"Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing","url":"https://erj.ersjournals.com/content/62/5/2300969 https://erj.ersjournals.com/content/62/5/2300969.abstract","volume":"62","year":"2023","bibtex":"@article{Achar2023,\r\nabstract = {With recent expansion in the use of bedaquiline and limited access to accurate drug susceptibility testing (DST), we read with concern of examples of the high prevalence of bedaquiline resistance detected in Mycobacterium tuberculosis isolates [1]. Choosing the most effective regimen for treatment of drug-resistant tuberculosis (TB) is crucially important [2] and requires accurate and timely DST. In the past decade, there has been wide roll-out of rapid molecular tests that can identify M. tuberculosis and mutations conferring rifampicin resistance (RR). However, for potent second-line drugs, such as fluoroquinolones [3], bedaquiline, pretomanid and linezolid, DST is either unavailable, has poor coverage or generates delayed results. To support clinicians, policymakers must provide pragmatic treatment recommendations for situations where a patient is diagnosed with RR-TB, but where additional DST results for second-line drugs are delayed or unavailable. Second-line drug susceptibility test results are frequently unavailable for people with TB. A method is proposed for comparing risks and benefits of different treatment regimens for rifampicin-resistant TB when accurate results are unavailable. https://bit.ly/46KHyl0},\r\nauthor = {Achar, Jay and Seddon, James A and Knight, Gwenan M and Dodd, Peter J and Esmail, Hanif and Hughes, Jennifer and McQuaid, C Finn},\r\ndoi = {10.1183/13993003.00969-2023},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Achar et al. - 2023 - Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susce.pdf:pdf},\r\nissn = {0903-1936},\r\njournal = {European Respiratory Journal},\r\nkeywords = {OA,fund{\\_}not{\\_}ack,letter},\r\nmendeley-tags = {OA,fund{\\_}not{\\_}ack,letter},\r\nmonth = {nov},\r\nnumber = {5},\r\npages = {2300969},\r\npmid = {37945035},\r\npublisher = {European Respiratory Society},\r\ntitle = {{Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing}},\r\nurl = {https://erj.ersjournals.com/content/62/5/2300969 https://erj.ersjournals.com/content/62/5/2300969.abstract},\r\nvolume = {62},\r\nyear = {2023}\r\n}\r\n","author_short":["Achar, J.","Seddon, J. A","Knight, G. M","Dodd, P. J","Esmail, H.","Hughes, J.","McQuaid, C F."],"key":"Achar2023","id":"Achar2023","bibbaseid":"achar-seddon-knight-dodd-esmail-hughes-mcquaid-guidingpragmatictreatmentchoicesforrifampicinresistanttuberculosisintheabsenceofsecondlinedrugsusceptibilitytesting-2023","role":"author","urls":{"Paper":"https://erj.ersjournals.com/content/62/5/2300969 https://erj.ersjournals.com/content/62/5/2300969.abstract"},"keyword":["OA","fund_not_ack","letter"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh"],"keywords":["oa","fund_not_ack","letter"],"search_terms":["guiding","pragmatic","treatment","choices","rifampicin","resistant","tuberculosis","absence","second","line","drug","susceptibility","testing","achar","seddon","knight","dodd","esmail","hughes","mcquaid"],"title":"Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing","year":2023}